Page last updated: 2024-09-05

sb 203580 and naproxen

sb 203580 has been researched along with naproxen in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(naproxen)
Trials
(naproxen)
Recent Studies (post-2010) (naproxen)
3,48941,1374,5511,0571,429

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)naproxen (IC50)
Prostaglandin G/H synthase 1Ovis aries (sheep)1.1642
Hormone-sensitive lipaseRattus norvegicus (Norway rat)1.2
Prostaglandin G/H synthase 1Homo sapiens (human)4.0203
Prostaglandin G/H synthase 2Homo sapiens (human)3.8725
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)0.06
Aldo-keto reductase family 1 member C3Homo sapiens (human)0.5867
Aldo-keto reductase family 1 member C2 Homo sapiens (human)1.26
Prostaglandin G/H synthase 2Ovis aries (sheep)3.36
Solute carrier family 22 member 6Homo sapiens (human)5.8
Prostaglandin G/H synthase 1 Rattus norvegicus (Norway rat)0.06

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adams, JL; Badger, AM; Boehm, JC; Bradbeer, J; Breton, JJ; Chabot-Fletcher, MC; Gallagher, TF; Garigipati, RS; Griswold, DE; Hillegass, LM; Laydon, JT; Lee, JC; Sheldrake, PL; Smietana, JM; Sorenson, ME1

Other Studies

1 other study(ies) available for sb 203580 and naproxen

ArticleYear
1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.
    Journal of medicinal chemistry, 1996, Sep-27, Volume: 39, Issue:20

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Arthritis; Bone Density; Cyclooxygenase Inhibitors; Cytokines; Imidazoles; Lipoxygenase Inhibitors; Mice; Mice, Inbred BALB C; Molecular Structure; Morpholines; Prostaglandin-Endoperoxide Synthases; Protein Kinases; Rats; Structure-Activity Relationship; Tumor Necrosis Factor-alpha

1996